New Jersey 2024-2025 Regular Session

New Jersey Assembly Bill A4327

Introduced
5/10/24  
Refer
5/10/24  

Caption

Revises statutory definition of "elevated blood lead level."

Impact

By revising the definition of elevated blood lead levels, A4327 seeks to improve the regulation of lead screening and prompt interventions in cases of lead exposure. The primary impact of this legislation will be on state laws related to public health, particularly those that protect children's welfare by addressing lead exposure risks from environmental sources such as water, paint, and building materials. This proactive approach is expected to enhance children’s health outcomes and lower the incidence of lead-related health issues across the state.

Summary

A4327 is a bill introduced in the New Jersey legislature aimed at revising the statutory definition of 'elevated blood lead level.' The bill amends P.L.1995, c.328, to redefine what constitutes an elevated blood lead level, specifying that it should now align with the most recent recommendations from the federal Centers for Disease Control and Prevention. This update intends to reflect current health standards, emphasizing the need for responsive action when such levels are detected. The bill is positioned within the framework of public health legislation directed at eliminating lead exposure, particularly among children.

Sentiment

The general sentiment surrounding A4327 is supportive, particularly among public health advocates and organizations focused on child welfare. Many view the bill as a necessary step to reinforce New Jersey’s commitment to addressing lead exposure, which has long been a public health concern. There is broad acknowledgment among health experts that reducing the threshold for what is considered an elevated blood lead level will allow for earlier identification and treatment of lead exposure, thus positively affecting community health.

Contention

Despite widespread support, some concerns may arise regarding the implementation of the revised definition and the potential adjustments required within existing health screening protocols. While the bill aims to streamline actions based on up-to-date criteria, discussions may emerge around the resource allocation for education and outreach to parents and affected communities. Additionally, the implications of tighter regulations on compliance for housing and businesses that may harbor lead-based materials could also be points of contention.

Companion Bills

NJ S3707

Same As Revises statutory definition of "elevated blood lead level."

Previously Filed As

NJ S3707

Revises statutory definition of "elevated blood lead level."

NJ A910

Revises and codifies schedule for childhood lead screenings.

NJ A4827

Revises and codifies schedule for childhood lead screenings.

NJ HB1110

Environment - Lead Poisoning Prevention - Elevated Blood Lead Level

NJ A2433

Requires health insurance companies to cover lead screenings for children 16 years of age or younger.

NJ A1681

Requires health insurance companies to cover lead screenings for children 16 years of age or younger.

NJ S1507

Revises and codifies schedule for childhood lead screenings; requires lead screenings as precondition of child's initial entry into school system.

NJ S1530

Revises and codifies schedule for childhood lead screenings; requires lead screenings as precondition of child's initial entry into school system.

NJ HB5368

Health: children; reporting requirements for blood lead levels for minors; modify, and update certain definitions. Amends sec. 5474 of 1978 PA 368 (MCL 333.5474) & adds sec. 5456a. TIE BAR WITH: HB 4532'23

NJ S1450

Requires health insurance companies to cover lead screenings for children 16 years of age or younger.

Similar Bills

No similar bills found.